Xing Zhou, Lichty Brian D
Infectious Diseases Division, Centre for Gene Therapeutics and Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ont., Canada.
Tuberculosis (Edinb). 2006 May-Jul;86(3-4):211-7. doi: 10.1016/j.tube.2006.01.017. Epub 2006 Feb 28.
Recombinant virus-vectored TB vaccines represent the most promising vaccine platform for boosting the protective immunity mediated by parenteral BCG prime immunization. A major advantage associated with virus-vectored vaccines is that they are potent respiratory mucosa-deliverable vaccines. A recombinant replication-deficient adenoviral (Ad) vector was engineered to express Mycobacterium tuberculosis (M.tb) Ag85A. Single administration of this Ad vaccine via the intranasal, but not intramuscular, route provided potent immune protection from pulmonary M.tb challenge. Respiratory mucosal boosting immunization with Ad vaccine was effective in enhancing T-cell activation and immune protection following parenteral DNA or BCG prime immunization. We have also recently developed a recombinant vesicular stomatitis virus-vectored (VSV) TB vaccine. Ad and VSV vector systems will be complementary to each other for BCG prime-virus vaccine boost immunization protocols.
重组病毒载体结核病疫苗是增强经肠胃外卡介苗初次免疫介导的保护性免疫的最有前景的疫苗平台。与病毒载体疫苗相关的一个主要优势是它们是有效的可经呼吸道黏膜递送的疫苗。构建了一种重组复制缺陷腺病毒（Ad）载体以表达结核分枝杆菌（M.tb）Ag85A。通过鼻内而非肌肉内途径单次接种这种Ad疫苗可提供针对肺部M.tb攻击的有效免疫保护。用Ad疫苗进行呼吸道黏膜加强免疫在肠胃外DNA或卡介苗初次免疫后可有效增强T细胞活化和免疫保护。我们最近还开发了一种重组水疱性口炎病毒载体（VSV）结核病疫苗。Ad和VSV载体系统在卡介苗初次免疫-病毒疫苗加强免疫方案中将相互补充。
Zotero 插件